Novartis Offers Gengraf Patients Transition Monitoring If Generic Is Pulled
Executive Summary
Novartis will offer blood level monitoring for transplant patients switching from Abbott's Gengraf to other cyclosporine products if the company's motion to have Gengraf removed from the market is granted
You may also be interested in...
Abbott/SangStat May Launch Oral Solution Gengraf To Replace SangCya
SangStat and Abbott are considering launching Abbott's generic cyclosporine oral solution Gengraf following the July 10 recall of SangStat's cyclosporine SangCya, the companies said.
SangStat/Abbott SangCya Co-Promotion Provides Entry To Managed Care
A Sangstat co-promotion agreement with Abbott for its SangCya oral cyclosporine products will provide the company with an experienced partner in the managed care and hospital marketing areas.
FDA Elimination Of Neoral "Microemulsion" Designation Disputed By Novartis
FDA's elimination of "microemulsion" dosage forms is unlawful, Novartis contended in a Feb. 11 lawsuit challenging FDA's approval of SangStat's generic version of Neoral (cyclosporine).